Thyrocare Technologies Ltd IPO Message Board (Page 75)

If anyone know ans. My query can i applye a diffrent demat account for ASBA diffrent BANK account demat a/c holder & bank a/c holder are diffrent

Pan no. & demat a/c diffrent hi but jis bank account se applye karna hi wo bank account oska nahi hi

YOU MAY APPLY FROM ANY BANK A/C

FRIENDS SBI TRADING SAVINGS AND DEMANT 3IN 1 SERVICE GOOD ? ARE THEY ALLOW IPO ORDERS ONLINE LIKE HDFC BANK AND ICICI BANK ?

Yes, they allow online through ASBA which is very fast. Moreover brokerage is also very low as compared to HDFC BANK AND ICICI BANK

I THINK FAIR VALUE OF THYROCARE ABOVE rs 800

May you share with us how did you arrive at this valuation ?

SP Tulsian Review on Thyrocare:
New issue (IPO) Analysis:
Diagnosing correctly

Thyrocare Technologies is entering primary market on Wednesday, 27th April 2016, with an offer for sale of upto 1.07 crore equity shares of Rs. 10 each, in the price band of Rs. 420 to Rs. 446 per share. Offer for sale by promoters comprises 5% of the issue, while balance 95% is being offered by PE investor CX Partners. Representing 20% of the post issue paid-up capital of the company, the issue will raise Rs. 451 crore and Rs. 479 crore at the lower and upper price band respectively and will close on Friday, 29th April, 2016.

Thyrocare Technologies is a Mumbai-based preventive healthcare and diagnostic chain, with a central processing laboratory at Navi Mumbai and 5 regional processing laboratories, offering 198 tests and 59 profiles of tests, having presence in 466 cities through 1,041 service providers. It’s wholly owned subsidiary Nueclear Healthcare Limited (NHL) operates molecular imaging centers in New Delhi, Navi Mumbai and Hyderabad.

For FY15, standalone revenue from operations grew 19% YoY to Rs. 187 crore, with total samples processed rising 30% YoY to 91 lakh. However, EBITDA only rose 6.5% YoY, to Rs. 80.25 crore (42.9% EBITDA margin vis-à-vis 48.1% in FY14), due to a whopping 43% YoY rise in employee cost to Rs.17 crore. Thus, net profit growth contracted to just 5% annually, with net profit coming in at Rs. 48.45 crores, to yield an EPS of Rs. 9.60 for FY15. Since subsidiary NHL is loss making, consolidated PAT for FY15 came in at Rs. 44.44 crores, with EPS of Rs. 8.80.

For 9 months ending 31-12-15, standalone total income is placed at Rs. 175 crores, with EBITDA at Rs. 74.50 crores, resulting in a margin of 42.7%, almost stagnant from FY15, rather a drop of 22 basis points! PAT for 9M FY16 was Rs. 43.60 crores, translating in an annualized EPS of Rs.11 for FY16. As of 31-12-15, company has no debt on its books, while cash and equivalents are Rs. 62 crores.

While its revenue has grown at a CAGR of 16% from Rs. 140 crores in FY13 to Rs. 187 crores in FY15, sadly, EBITDA CAGR has been much lower at 8%, with EBITDA rising from Rs. 69 crores to just Rs. 80 crores during FY13-15, while PAT has actually fallen from Rs. 56.80 crores in FY13 to Rs. 48.45 crores in FY15. Higher personnel cost and depreciation are the culprits for this de-growth in bottom line.

At the upper end of price band of Rs. 446 per share, market cap of the company will be Rs. 2,396 crores and enterprise value (EV) Rs. 2,330 crores. EV/EBITDA multiple based on estimated FY16 EBITDA of Rs. 105 crores, given that Q4 is seasonally stronger for the company, is at 22 times. For FY16, company is likely to report an EPS of closer to Rs. 11 per share, resulting in PE ratio of 40 times, based on FY16 earnings.

Dr. Lal Pathlabs, with 172 labs, 1,554 centres and 7,000+ pick-up points, is currently ruling at PE multiple of over 55x and EV/EBITDA multiple closer to 39x, despite 9MFY16 EBITDA margin of only 26.2%, much lower than Thyrocare’s 40%+. This implies that the latter is valued at a discount to its listed peer, may be due to its lower size, as compared to Dr. Lal.

Although Thyrocare has comparatively lower network strength vis-à-vis Dr. Lal PathLabs, its superior margins coupled with double digit growth are seen positive. Thanks to focus on preventive and wellness health segments by diagnostic chains rather than focus on disease, backed by increasing awareness of the younger generation, preventive diagnostic services segment is poised to grow steadily, which is beneficial for the sector as a whole and this company, in particular.

Historically, diagnostic stocks are ruling at abysmally high PE multiples, which is unsustainable over a longer term, as new players get listed on the bourses, leading to a fairer price discovery. But, as of now, we have to live with expensive valuations for such stocks (partly due to the sector growth rates and partly due to scarcity premium being accorded to them) or be left out in the process to invest.

While the pricing of Thyrocare issue is not cheap, one can apply for listing gains, as also, with a MT view, as an investor.

i am having bank account in hdfc and demat account in zerodha, i have enabled asba in hdfc,

i have one more demat account in icici and account in icicidirect so can i apply twice one with icici and one with zerodha/hdfc ?

if yes how will shares get credited and where will money go if i sell it ?

It doesn''t matter if you have multiple brokerage accounts. What matters is the PAN number. You cannot apply from different accounts using same PAN number, it will get rejected.

http://www.ndtv.com/video/player/news/knowing-thyrocare-technologies-ipo-opens-on-april-27/412959

Demat account holder & bank account holder alag-alag hone se appliction rejact to nahi hoga

yes u can u need to register his Dp details in your SBI account... SBI allows upto 5 such Asba registration from one account

Happy Birthday!!!
TTL is Next Dr.Lal huge demands in Grey Market. Bumper listing expected.
Rajkot Full Swing Buying

comparing Dr lal and TTL which is better and how much can it list based on Dr lal price
if you want to really value peers the ROE is most important it is same as what compound interest will do to ur money higher the rate better the return

A 10% rate take 7years plus to double and 20% takes 4 years to double.


same a higher return of equity

so now let compare these two the return in Dr lal is almost double which means this will also grow in double size if all other thing is same however here we find the EPS is all better in Dr lal so this will also have good effect on it future growth as it will start at a higher base.


presently Dr lal MC is approx 85 billion rupee and Thyrocare is approx 24 billion

if say the growth is half in Thyrocare compare to Dr lal my NAV would 42.5 billion less another 20% for less EPS meaning i can give it a MC of 34 Billion rupee and upside of 10 Billion which gives me a value of 632 rupee per share when the issue is offered at 446 an upside of at least Rs 185 premium of listing

This just based on RONW if i do a PE modelling the result will be more favourable price for THyrocare

a price of 748 is possible if u compare to Dr lal however that is not a fair value IMO

Apply in this. On listing may be touch 600. Also good response from grey market.

Thyorcare ... Punters are super bullish on this counter ... expect listing @ Rs.750 - Rs.800

employee qouta h kya is ipo m ? how much percent

Dear Eagleeye ji,

Why u give up to 75% gain for listing.

Kostak rate 1000-1200 and gmp 200. And listing price 75%. Can u explain of logic

Septa ji
I have a close friend who sometimes does not want to subscribe to an IPO. However he told me that if I am interested, then I can use his DP A/C.
My question is :
Can I register his name in my ASBA Saving bank A/C & apply online utilising my funds. He is ready to sign the "Deliver Instruction Slip (DIS)" in advance for the transfer of allotted shares from his DP to my DP.
Is there anyone who has such arrangement

NKD that is possible then tax implication would be in ur friend account.... One can fund anyone in buying asset no issue it will be consider as loan in case of close family it can be also consider as gift with no tax implication however any profit or loss on this investment will be in the hands of ur friend or loan taker or gift taker.

one loop is there however it is not worth the trouble of 3000 to 5000 gain

have all the transaction in ur friends name say u make a profit of 5001 on the funds u gave u charge his a interest of 5000 so he will get Rupee one profit on short term gain and u will get 5000 profit as interest income if ur slab rate is 10% it is alright however if it higher 20% to 30% then u pay higher tax.

but this strategy is alright if u make gain in case of loss u need to pay the loss to ur friend and u cannot account this in ur books

Septa ji If my friend transfer the shares to my account and i sold it to my account then what would be tax liability for my friend for example .. my friend allotted 1000/- (rs) share on behalf of my saving account asba then he transferred the shares to my demat account .. at the time of transfer the shares value was 1050/- i sold at 1100/- sir now the question arises ...

1 Is this is a matter of benami transaction ?

2 what are tax liability of both of us ?

3 If as a goodwill gesture both us paying taxes for the above transaction then still it is called benami.

4 what are the charges and penalty for benami transaction

5 Is there any more document required to take it, as in easyway.

I think very hard to get allotment.
Dr. Lal received approx. 5.5 lac application in retail so if we see these type of subcription.

Thyrocare GMP 202 - 205 (Stable)
Ujjivan GMP 38 - 40 (Stable)

All Grey Brokers in Jaipur & Delhi are busy in a Wedding

eagleye how u get gmp info any website or blog for that ?

Yeah ...

Chittorgarh.com padharo sa

Latest application rate in ahmedabad

Apply in Thyrocare with a target of 650+

Short Term Investors exit Equitas at 142+
Long term investors can add again after correction. Few events such as Mergers of subsidiary will create pressure on this stock.

Septa what ia your view on Suzlon ?
All positive news from 1 month still stock is not going up
Would you hold this stock for long ?

i stay away from penny stock

i am a retail investor,how can i invest in HNI/NII category and like in retail application we write "cut-off" price, are other category (hni/nii) requires priced bids , plz share ?

Thyrocare = 1300

Ujjivan = 1200

Keep dreaming

@hasija it''s Kostak rates not share price.

Should we apply for this ipo

1 seving account me se kitne from bhar shakte hai.....please reply any on....

5

5